Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Biollaz

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|May 21, 2005
The importance of assessing the dose actually administered in pharmacokinetic trialsThierry Buclin, Nancy Perrottet, Jerome Biollaz
Cancer Letters|February 23, 2011
Letter to the editor response to the article of Luisa Lina Villa HPV prophylactic vaccination: the first years and what to expect from now, in pressJean Pierre Spinosa, Catherine Riva, Jerome Biollaz
Wiener Medizinische Wochenschrift (1946)|February 20, 2009
"Iatrogenicity cascade": doing harm by treating harm?Claudia Christina Wagner, Jerome Biollaz, Markus Zeitlinger, et al.
The Lancet. Oncology|November 30, 2010
Who is in charge of assessing therapeutic drug monitoring? The case of imatinibThierry Buclin, Nicolas Widmer, Jerome Biollaz, et al.
Clinical Pharmacokinetics|August 5, 2009
Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurementsNancy Perrottet, Laurent A Decosterd, Pascal Meylan, et al.
Neurology|May 20, 2016
Pregnancy outcome following maternal exposure to pregabalin may call for concernUrsula Winterfeld, Paul Merlob, David Baud, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|May 21, 2005
The importance of assessing the dose actually administered in pharmacokinetic trialsThierry Buclin, Nancy Perrottet, Jerome Biollaz
Cancer Letters|February 23, 2011
Letter to the editor response to the article of Luisa Lina Villa HPV prophylactic vaccination: the first years and what to expect from now, in pressJean Pierre Spinosa, Catherine Riva, Jerome Biollaz
Wiener Medizinische Wochenschrift (1946)|February 20, 2009
"Iatrogenicity cascade": doing harm by treating harm?Claudia Christina Wagner, Jerome Biollaz, Markus Zeitlinger, et al.
The Lancet. Oncology|November 30, 2010
Who is in charge of assessing therapeutic drug monitoring? The case of imatinibThierry Buclin, Nicolas Widmer, Jerome Biollaz, et al.
Clinical Pharmacokinetics|August 5, 2009
Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurementsNancy Perrottet, Laurent A Decosterd, Pascal Meylan, et al.
Neurology|May 20, 2016
Pregnancy outcome following maternal exposure to pregabalin may call for concernUrsula Winterfeld, Paul Merlob, David Baud, et al.
Pageof 1